Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “PIK3CA Mutation”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT04997902
What this trial is testing

Combination Trial of Tipifarnib and Alpelisib in Adult Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)

Who this might be right for
HNSCC
Kura Oncology, Inc. 45
Testing effectiveness (Phase 2)Looking for participantsNCT06789913
What this trial is testing

Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation (The ReInspire Study)

Who this might be right for
PIK3CA-Related Overgrowth Spectrum (PROS)Lymphatic MalformationsVascular Malformations+5 more
Relay Therapeutics, Inc. 277
Testing effectiveness (Phase 2)Looking for participantsNCT07558733
What this trial is testing

Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer

Who this might be right for
HR+ HER2- Breast Cancer
Faeth Therapeutics 32
Testing effectiveness (Phase 2)Looking for participantsNCT07368998
What this trial is testing

To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast Cancer

Who this might be right for
Breast Cancer
Hoffmann-La Roche 80
Not applicableStudy completedNCT04976439
What this trial is testing

Patogenic Mutation in 5 Genes

Who this might be right for
Colorectal CancerAPC Gene MutationTP53 Gene Mutation+3 more
Dr Cipto Mangunkusumo General Hospital 22
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07441512
What this trial is testing

A Phase II, Single-arm Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Eribulin in Pretreated Advanced Triple-negative Breast Cancer Harboring a PIK3CA Mutation

Who this might be right for
TNBC - Triple-Negative Breast CancerTNBC
Hu Hai 26
Not applicableLooking for participantsNCT07347600
What this trial is testing

Evaluate the Effectiveness and Safety of Inavolisib in Participants With Endocrine-resistant, PIK3CA-mutated, Hormone Receptor-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Locally Advanced Breast CancerMetastatic Breast Cancer
Hoffmann-La Roche 500
Testing effectiveness (Phase 2)Looking for participantsNCT06463028
What this trial is testing

Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer

Who this might be right for
Endometrial Cancer
Faeth Therapeutics 40
Testing effectiveness (Phase 2)Study completedNCT06132932
What this trial is testing

WX390 in Patients With Advanced Solid Tumors With PIK3CA Mutations

Who this might be right for
PIK3CA Mutation-Related Tumors
Shanghai Jiatan Pharmatech Co., Ltd 38
Testing effectiveness (Phase 2)Study completedNCT02449538
What this trial is testing

Study to Evaluate the Safety and Efficacy of Everolimus, in Subjects With PIK3CA Amplification, PTEN Loss and PIK3CA Mutation Refractory Solid Tumors

Who this might be right for
Solid Tumor
Samsung Medical Center 10
Large-scale testing (Phase 3)Looking for participantsNCT05948943
What this trial is testing

Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.

Who this might be right for
Lymphatic Malformations
Novartis Pharmaceuticals 232
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07748208
What this trial is testing

A Study Evaluating the Safety of Inavolisib and Fulvestrant With or Without Palbociclib in Participants With Advanced Breast Cancer (ABC) and Type 2 Diabetes

Who this might be right for
Breast CancerDiabetes Type II
Hoffmann-La Roche 40
Testing effectiveness (Phase 2)Active Not RecruitingNCT03994796
What this trial is testing

Genetic Testing in Guiding Treatment for Patients With Brain Metastases

Who this might be right for
CDK Gene MutationMetastatic Malignant Neoplasm in the BrainMetastatic Malignant Solid Neoplasm+4 more
Alliance for Clinical Trials in Oncology 50
Testing effectiveness (Phase 2)WithdrawnNCT01501604
What this trial is testing

BKM120 in Cancers With PIK3CA Activating Mutations

Who this might be right for
Lung CancerBreast CancerColorectal Cancer+2 more
Massachusetts General Hospital
Early research (Phase 1)Study completedNCT01473095
What this trial is testing

Phase 1 Dose Escalation Study of ARQ 092 in Adult Subjects With Advanced Solid Tumors and Recurrent Malignant Lymphoma

Who this might be right for
Solid TumorMalignant LymphomaTumor
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) 120
Testing effectiveness (Phase 2)Ended earlyNCT01708161
What this trial is testing

A Phase Ib/II Study of the Combination of BYL719 Plus AMG 479 in Adult Patients With Selected Solid Tumors

Who this might be right for
PIK3CA Mutated Advanced Solid TumorsPIK3CA Amplified Advanced Solid Tumors
Novartis Pharmaceuticals 47
Early research (Phase 1)Study completedNCT03767335
What this trial is testing

MEN1611 With Trastuzumab (+/- Fulvestrant) in Metastatic Breast Cancer

Who this might be right for
Advanced or Metastatic Breast Cancer
Menarini Group 62
Early research (Phase 1)Looking for participantsNCT05216432
What this trial is testing

First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer

Who this might be right for
PIK3CA MutationSolid Tumor, AdultHER2-negative Breast Cancer+4 more
Relay Therapeutics, Inc. 930
Not applicableStudy completedNCT02449564
What this trial is testing

The Pilot Study Evaluate the Safety and Efficacy of Sirolimus in Patients With PIK3CA Mutation and/or PIK3CA Amplification Refractory Solid Tumors

Who this might be right for
Solid Tumor
Samsung Medical Center 5
Testing effectiveness (Phase 2)Ended earlyNCT04409145
What this trial is testing

First in Human Trial of Topical VT30 in Pts With Venous/Lymphatic Malformations Assoc With PIK3CA or TEK Gene Mutations

Who this might be right for
Venous MalformationLymphatic MalformationVenolymphatic Malformation
Venthera, Inc., a BridgeBio company 15
Next Page